Cerity Partners
IOVA icon

Cerity Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Cerity Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
95,709
+76,322
+394% +$290K ﹤0.01% 2580
2026
Q1 		$68K Buy
+19,387
New +$62K ﹤0.01% 3070

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cerity Partners's IOVA Position: Q2 2026 in Review

Cerity Partners increased its Iovance Biotherapeutics (IOVA) stake by 394% in Q2 2026, buying an estimated $290K and bringing the position to 95,709 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #2580.

Cerity Partners first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Cerity Partners held 95,709 shares of Iovance Biotherapeutics worth $398K as of Q2 2026.
  • Cerity Partners bought 76,322 Iovance Biotherapeutics shares in Q2 2026, an estimated $290K.
  • Iovance Biotherapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2580 holding.
  • Cerity Partners first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.